synthetic biologyGraveyard archive2012–2025

Synthego

Synthego set out to do for genome engineering what SpaceX did for rockets — industrialize it — and for a while it worked, before debt and a biotech-tools downturn caught up. Founded in 2012 in Redwood City by ex-SpaceX engineer brothers Paul and Michael Dabrowski, Synthego became a default supplier of synthetic guide RNA and engineered cells to CRISPR labs worldwide, turning bespoke bench chemistry into an on-demand, automated reagent service through its CRISPRevolution product line and later GMP clinical-grade manufacturing. Backed by Founders Fund, 8VC, Wellington Management, the SoftBank Vision Fund 2 and CRISPR co-inventor Jennifer Doudna, it raised more than $450 million, capped by a $200 million Series E in February 2022 led by Perceptive Advisors that reportedly valued it around $1.

Years active

2012–2025

Peak valuation

$1.3B

Total raised

$450M

Peak headcount

~525

Rocket engineers meet CRISPR

Synthego was founded in 2012 in Redwood City, California by brothers Paul and Michael Dabrowski, both former SpaceX engineers who wanted to apply the manufacturing discipline of rocketry to biology. Their insight was that CRISPR genome editing, then an artisanal process in which every lab designed, synthesized and validated its own components, could be industrialized: standardized, automated and delivered as an off-the-shelf reagent. The core product was chemically modified synthetic single-guide RNA, produced at high throughput and high purity, alongside predesigned guide libraries and engineered knockout cell lines. Researchers could order online and receive validated CRISPR components as commodities rather than build them by hand — a genuine change in how genome-editing science got done.

The default CRISPR supplier

Synthego launched its CRISPRevolution product line in 2016 and rode the explosion of CRISPR research to become a go-to reagent supplier for academic and biopharma genome-editing labs. The money followed: a $41 million Series B led by 8VC in early 2017, a $110 million Series C led by Peter Thiel's Founders Fund in October 2018, and marquee validation when CRISPR co-inventor Jennifer Doudna aligned with the company. As cell and gene therapies moved toward the clinic, Synthego built GMP clinical-grade manufacturing to supply not just researchers but drug developers, positioning itself as picks-and-shovels infrastructure for the entire genome-editing industry rather than a single-drug bet.

The $200 million unicorn round

In February 2022, Synthego raised a $200 million Series E led by Perceptive Advisors, with the SoftBank Vision Fund 2, Wellington Management, RA Capital, Declaration Partners and others joining. The round pushed total capital raised past $450 million and reportedly valued Synthego around $1.3 billion, minting a unicorn at the peak of the pandemic-era biotech boom. The plan was to scale automation, expand GMP capacity and carry the industrialized-CRISPR thesis from research reagents into clinical-grade manufacturing. It was, in hindsight, the top of the market: capital for life-science tools companies was about to contract sharply, and Synthego had built a cost structure sized for continued abundance.

When the money stopped

The downturn exposed the gap between Synthego's spending and its revenue. Heavy investment in automation, technology and operations consistently outpaced sales; margins compressed even as revenue grew; and the company's debt-service burden rose more than tenfold, according to its own restructuring disclosures. A roughly 20% workforce cut of about 105 people in November 2022 signaled the strain. As the biotech-tools venture market stayed frozen, Synthego reached a point in early 2025 where it could no longer generate cash flow sufficient to service its debt. It was the classic infrastructure-company trap: the reagents were real and widely used, but the capital-intensive machine built to make them was too expensive to sustain without cheap money.

The credit-bid takeover

On May 5, 2025, Synthego filed for Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware, listing assets of $50–100 million against liabilities of $100–500 million. Its lead lender, Perceptive Advisors — already the Series E lead and now the prepetition secured creditor — provided a $50 million debtor-in-possession facility and served as stalking-horse bidder, exchanging roughly $85 million in debt for substantially all of Synthego's assets. The acquisition closed on July 18, 2025; the old debtor entity was renamed and the business continued under Perceptive's ownership using the Synthego brand. More than $450 million raised and a $1.3 billion valuation ended in a creditor takeover, a case study in how the tools layer of synthetic biology — indispensable but capital-hungry — fared worst when the funding cycle turned.

What worked, what broke

What worked

Industrialized CRISPR reagents — turning synthetic guide RNA and engineered cells from bespoke bench work into an on-demand, automated commodity through the CRISPRevolution product line.
Became a default supplier of guide RNA to academic and biopharma genome-editing labs worldwide, embedding itself as infrastructure for the CRISPR research boom.
Built GMP clinical-grade manufacturing to extend from research reagents into supplying cell- and gene-therapy developers heading to the clinic.
Raised more than $450 million from marquee backers including Founders Fund, 8VC, Wellington Management and the SoftBank Vision Fund 2, and aligned with CRISPR co-inventor Jennifer Doudna.
Reached a reported $1.3 billion valuation in its 2022 Series E, one of the best-capitalized genome-engineering tools companies of the era.

What broke

Spending on automation, technology and operations chronically outpaced revenue, producing sustained cash burn even as sales grew.
Margin compression combined with a more-than-tenfold rise in debt-service costs left the company unable to service its debt by early 2025.
Over-leverage into a biotech-tools downturn that froze venture funding, removing the cheap capital the capital-intensive model depended on.
A cost structure sized at the 2022 market peak that proved impossible to sustain once the funding cycle turned, forcing a 2022 workforce cut and eventually bankruptcy.
Dependence on its lead investor Perceptive Advisors, which converted its secured position into control through a credit bid, wiping out prior equity.

Sources

Obituary authored Jul 2, 2026 via Sonnet 4.5 + web_search.

What’s new

Join affiliate network